54.51
-0.12(-0.22%)
Currency In USD
| Previous Close | 54.63 |
| Open | 54.6 |
| Day High | 55.08 |
| Day Low | 54.28 |
| 52-Week High | 61.48 |
| 52-Week Low | 11.17 |
| Volume | 90,800 |
| Average Volume | 149,433 |
| Market Cap | 602.86M |
| PE | -21.55 |
| EPS | -2.53 |
| Moving Average 50 Days | 42.77 |
| Moving Average 200 Days | 25.91 |
| Change | -0.12 |
If you invested $1000 in Palvella Therapeutics, Inc. (PVLA) since IPO date, it would be worth $3,206.47 as of September 16, 2025 at a share price of $54.51. Whereas If you bought $1000 worth of Palvella Therapeutics, Inc. (PVLA) shares 0 years ago, it would be worth $3,206.47 as of September 16, 2025 at a share price of $54.51.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Palvella Therapeutics Completes Enrollment in Phase 2 TOIVA Trial of QTORIN™ Rapamycin for Cutaneous Venous Malformations
GlobeNewswire Inc.
Yesterday at 11:30 AM GMT
Phase 2 TOIVA trial successfully met recruitment target, enrolling 16 subjects at leading vascular anomaly centers; top-line data expected in mid-December 2025 Venous malformations are the most common type of vascular malformation, with skin involvem
Palvella Therapeutics Strengthens Leadership with Appointment of Accomplished Scientist and Biopharmaceutical Executive David W. Osborne, Ph.D. as Chief Innovation Officer
GlobeNewswire Inc.
Sep 03, 2025 11:30 AM GMT
Co-Founder and former Chief Technical Officer of Arcutis Biotherapeutics brings extensive topical product development experience, including track record of translating science into commercially available therapies Dr. Osborne to guide expansion of QT
Palvella Therapeutics to Present at Upcoming Healthcare Investor Conferences
GlobeNewswire Inc.
Aug 28, 2025 11:30 AM GMT
WAYNE, Pa., Aug. 28, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: PVLA) Palvella Therapeutics, Inc. (Palvella), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare